<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28696286</article-id>
<article-id pub-id-type="pmc">5544319</article-id>
<article-id pub-id-type="publisher-id">201705521</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1705521114</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Psychological and Cognitive Sciences</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism</article-title>
<alt-title alt-title-type="short">Oxytocin treatment for autism</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Parker</surname>
<given-names>Karen J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oztan</surname>
<given-names>Ozge</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Libove</surname>
<given-names>Robin A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sumiyoshi</surname>
<given-names>Raena D.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jackson</surname>
<given-names>Lisa P.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karhson</surname>
<given-names>Debra S.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Summers</surname>
<given-names>Jacqueline E.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hinman</surname>
<given-names>Kyle E.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Motonaga</surname>
<given-names>Kara S.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Phillips</surname>
<given-names>Jennifer M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carson</surname>
<given-names>Dean S.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garner</surname>
<given-names>Joseph P.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hardan</surname>
<given-names>Antonio Y.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup>Department of Psychiatry and Behavioral Sciences, <institution>Stanford University</institution>, Stanford, <addr-line>CA</addr-line> 94305;</aff>
<aff id="aff2"><sup>b</sup>Department of Pediatrics, <institution>Stanford University</institution>, Stanford, <addr-line>CA</addr-line> 94305;</aff>
<aff id="aff3"><sup>c</sup>Department of Comparative Medicine, <institution>Stanford University</institution>, Stanford, <addr-line>CA</addr-line> 94305</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>1</sup>To whom correspondence should be addressed. Email: <email>kjparker@stanford.edu</email>.</corresp>
<fn fn-type="edited-by">
<p>Edited by Michael L. Platt, University of Pennsylvania, Philadelphia, PA, and accepted by Editorial Board Member Michael S. Gazzaniga June 6, 2017 (received for review April 17, 2017)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: K.J.P., R.A.L., J.M.P., D.S.C., and A.Y.H. designed research; K.J.P., O.O., R.A.L., R.D.S., L.P.J., D.S.K., J.E.S., K.E.H., K.S.M., J.M.P., D.S.C., and A.Y.H. performed research; O.O. contributed new reagents/analytic tools; K.J.P., J.E.S., and J.P.G. analyzed data; K.J.P., O.O., J.P.G., and A.Y.H. wrote the paper; and K.J.P. and A.Y.H. provided funding for the research.</p>
</fn>
<fn fn-type="COI-statement">
<p>The authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>25</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>10</day>
<month>7</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>114</volume>
<issue>30</issue>
<fpage>8119</fpage>
<lpage>8124</lpage>
<permissions>
<license license-type="open-access">
<license-p>Freely available online through the PNAS open access option.</license-p>
</license>
</permissions>
<self-uri xlink:href="pnas.201705521.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>Autism spectrum disorder (ASD) is characterized by social deficits. Emerging evidence suggests that the neuropeptide oxytocin, which regulates mammalian social functioning, may be a promising treatment for ASD. However, prior oxytocin treatment trials in ASD patients have produced equivocal results, perhaps because of variability in patients’ underlying neuropeptide biology. Here we provide evidence that oxytocin treatment improves social abilities in children with ASD and that individuals with the lowest pretreatment blood oxytocin concentrations benefit the most from oxytocin administration. These findings reveal a personalized component to oxytocin treatment which may have important implications for accurately testing oxytocin’s therapeutic potential, both for ASD and for a broad range of developmental and psychiatric disorders in which patients exhibit social impairments.</p>
</abstract>
<abstract>
<p>Autism spectrum disorder (ASD) is characterized by core social deficits. Prognosis is poor, in part, because existing medications target only associated ASD features. Emerging evidence suggests that the neuropeptide oxytocin (OXT) may be a blood-based biomarker of social functioning and a possible treatment for ASD. However, prior OXT treatment trials have produced equivocal results, perhaps because of variability in patients’ underlying neuropeptide biology, but this hypothesis has not been tested. Using a double-blind, randomized, placebo-controlled, parallel design, we tested the efficacy and tolerability of 4-wk intranasal OXT treatment (24 International Units, twice daily) in 32 children with ASD, aged 6–12 y. When pretreatment neuropeptide measures were included in the statistical model, OXT compared with placebo treatment significantly enhanced social abilities in children with ASD [as measured by the trial’s primary outcome measure, the Social Responsiveness Scale (SRS)]. Importantly, pretreatment blood OXT concentrations also predicted treatment response, such that individuals with the lowest pretreatment OXT concentrations showed the greatest social improvement. OXT was well tolerated, and its effects were specific to social functioning, with no observed decrease in repetitive behaviors or anxiety. Finally, as with many trials, some placebo-treated participants showed improvement on the SRS. This enhanced social functioning was mirrored by a posttreatment increase in their blood OXT concentrations, suggesting that increased endogenous OXT secretion may underlie this improvement. These findings indicate that OXT treatment enhances social abilities in children with ASD and that individuals with pretreatment OXT signaling deficits may stand to benefit the most from OXT treatment.</p>
</abstract>
<kwd-group>
<kwd>autism</kwd>
<kwd>biomarkers</kwd>
<kwd>clinical trial</kwd>
<kwd>oxytocin</kwd>
<kwd>social functioning</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">Mosbacher Family Fund for Autism Research</funding-source>
<award-id rid="sp1">N/A</award-id>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">The Child Health Research Institute</funding-source>
<award-id rid="sp2">N/A</award-id>
</award-group>
<award-group id="gs3">
<funding-source id="sp3">Yani Calmidis Memorial Fund for Autism Research</funding-source>
<award-id rid="sp3">N/A</award-id>
</award-group>
<award-group id="gs4">
<funding-source id="sp4">Autism Speaks (Autism Speaks Inc.)<named-content content-type="funder-id">100000073</named-content></funding-source>
<award-id rid="sp4">7895</award-id>
</award-group>
<award-group id="gs5">
<funding-source id="sp5">Stanford University School of Medicine Postdoctoral Fellowship</funding-source>
<award-id rid="sp5">N/A</award-id>
</award-group>
<award-group id="gs6">
<funding-source id="sp6">HHS | NIH | National Institute of Mental Health (NIMH)<named-content content-type="funder-id">100000025</named-content></funding-source>
<award-id rid="sp6">T32MH019908</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="6"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>